An observational study in Coronary Artery Disease, Cardiovascular Risk Factor and Coronary Arteriosclerosis, sponsored by Aristotle University Of Thessaloniki. Status unknown at 1 site in Greece. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-09.
Sponsored by Aristotle University Of Thessaloniki · Observational
Among 75 studies in Coronary Artery Disease with a site in Greece — 12 open to participants now, 18 under way, 3 of them phase 3. Coronary Artery Disease · Greece.
Among the 75 studies in Coronary Artery Disease with a site in Greece, this one is the 16th largest by enrollment of the 24 observational ones that give a count, is one of 3 that started in 2016, is one of 24 observational ones, and was the 43rd registered.
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's enrollment of 270 is below the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →12 of the 75 studies in Coronary Artery Disease with a site in Greece are open now.
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 47 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 11 · Phase 4 13
First in 2003; this study’s year is marked. 3 started in 2016.
Median enrollment 120 across the 51 interventional studies, 727 across the 24 observational. Of the 46 that completed or were terminated, 7 (15%) have results posted.
16 of 75 have an industry lead sponsor. The 10 most frequent:
Aristotle University Of Thessaloniki is the lead sponsor of 282 studies on the registry; 55 are open to participants now.
Aristotle University Of Thessaloniki has 6 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT07839806National and Kapodistrian University of AthensDrug-coated Balloons Versus Drug-eluting Stents for de Novo Small-vessel Coronary Artery Disease | 2026-12-03 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06839755Hellenic Society of CardiologyThe Positive Prognostic Value of Stress Echocardiography - AMPHIPOLIS STUDY | 2027-01-31 |
Among the 75 studies in Coronary Artery Disease with a site in Greece, from their registry updates:
The purpose of the research project is to investigate the potential association of 6 genetic polymorphisms with the complexity and the severity of coronary artery disease (SYNTAX score). The aim of the study is to combine genetic, clinical and laboratory data in order to create a prognostic tool that will enable an individualized therapeutic patient approach.
This study focus on the prediction of future risk of cardiovascular events, assessing the severity and complexity of coronary artery disease by incorporating genetic information into the SYNTAX score and providing personalized therapeutic guidance to patients. The ultimate goal of the study would be to identify, design and develop a panel of genetic markers that in combination with clinical and angiographic information will be a reliable tool for predicting cardiovascular risk for future adverse events. Clinical and genetic patient information are systematically collected in a fashion that will enable also retrospective evaluation.
Patients between 18 years to 90 years at entry, of both genders, who are admitted in the Department of Cardiology in the AHEPA University General Hospital of Thessaloniki and undergo coronary angiography for clinical purposes will be studied
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with nonobstructive CAD (≤50 % diameter stenosis)
Genetic: SNPs associated with CAD
Low SYNTAX group
Genetic: SNPs associated with CAD
Intermediate-High SYNTAX group
Genetic: SNPs associated with CAD
Genotyping will be carried out by Real-Time PCR
Relationship between genetic risk variants and the SYNTAX score [All-comers population]
The investigators will evaluate the effects of 6 known genetic variants associated with risk of Coronary Artery Disease on the extend and severity of coronary atherosclerosis \[as assessed by the SYNTAX score\] in patients with significant CAD on coronary angiography, both individually and combined in a Genetic Risk Score
Time frame: 12 months
MACCEs
Cardiovascular death, myocardial infarction, stent thrombosis, any re-intervention and stroke
Time frame: 12 months
Predictive value of combining a Genetic Risk Score & SYNTAX score for the prediction of 1-year MACCEs
A Genetic Risk Score will be calculated as the weighted sum of alleles of 6 single nucleotide polymorphisms previously associated with CAD \[The GRS will be constructed by summing the number of risk alleles (0/1/2) for each of the 6 SNPs weighted by their estimated effect sizes\]. SYNTAX score is a coronary lesion complexity scoring system and represented by a single number.
Time frame: 12 months
Ankle-Brachial Index
A tool for diagnosing peripheral artery disease but also an indicator of systemic atherosclerosis \[represented by a single number\]
Time frame: At hospital admission
Left Ventricular Ejection Fraction
LVEF \[%\] as assessed by echocardiography
Time frame: At hospital admission & 12 months after discharge from hospital
Neutrophil to Lymphocyte Ratio
NLR \[represented by a single number\]
Time frame: At hospital admission
Red Cell Distribution Width
RDW \[%\]
Time frame: At hospital admission
Mean Platelet Volume
MPV \[fL\]
Time frame: At hospital admission
Glomerular Filtration Rate
GFR as assessed by CKD-EPI formula \[mL/min/1.73m²\]
Time frame: At hospital admission
High Density Lipoprotein
HDL \[mg/dL\]
Time frame: At hospital admission
Plan to share: Undecided
Ran from Sep 2016 to primary completion in Jun 2018, 21 months.
Of 634 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 21 months is below that.
Counting every sponsor, half of 759 studies reached it within 40 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aristotle University Of Thessaloniki →